International Journal of Cancer Management

Published by: Kowsar

Cost-Utility Analysis of IEV Drug Regimen Versus ESHAP Drug Regimen for the Patients With Relapsed and Refractory Hodgkin and Non-Hodgkin’s Lymphoma in Iran

Nahid Hatam 1 , Mehdi Dehghani 2 , Mostafa Habibian 3 and Abdosaleh Jafari 4 , *
Authors Information
1 School of Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Hematology and Oncology Ward, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
3 Student Research Committee, Department of Health Economics, School of Management and Information ‎Sciences, Shiraz University of Medical Sciences, Shiraz, IR Iran
4 Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, IR Iran
Article information
  • Iranian Journal of Cancer Prevention: October 28, 2015, 8 (5); e4061
  • Published Online: October 27, 2015
  • Article Type: Research Article
  • Received: September 15, 2015
  • Accepted: October 7, 2015
  • DOI: 10.17795/ijcp-4061

To Cite: Hatam N, Dehghani M, Habibian M, Jafari A. Cost-Utility Analysis of IEV Drug Regimen Versus ESHAP Drug Regimen for the Patients With Relapsed and Refractory Hodgkin and Non-Hodgkin’s Lymphoma in Iran, Int J Cancer Manag. 2015 ; 8(5):e4061. doi: 10.17795/ijcp-4061.

Abstract
Copyright © 2015, Iranian Journal of Cancer Prevention.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Stewart BW, Wild CP. World Cancer Report 2014. 2014;
  • 2. Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis. 2010; 31(1): 100-10[DOI][PubMed]
  • 3. Canadian Cancer Statistics. 2008;
  • 4. Altekruse S, Kosary C, Krapcho M, Neyman N, Aminou R, Waldron W. SEER Cancer Statistics Review, 1975-2007. 2010;
  • 5. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. 2012; 13(8): 790-801[DOI]
  • 6. Jaffe E, Harris N, Stein H, Vardiman J. WHO classification: Pathology and genetics of tumors of haematopoietic and lymphoid tissues. Ann Oncol. 2001; 13(3): 490-1[DOI]
  • 7. Townsend W, Linch D. Hodgkin's lymphoma in adults. Lancet. 2012; 380(9844): 836-47[DOI]
  • 8. Mousavi S. Executive Guideline for Registering and Reporting Cancer Cases. 2007; : 22
  • 9. Iranian National Cancer . Iranian national cancer registration report, 2010. 2010;
  • 10. The GlobalBurden of Disease. 2008;
  • 11. Khajedaluee M, Dadgarmoghaddam M, Saeedi R, Izadi-Mood Z, Abrishami M, Zamani M. Mortality, Morbidity, Survival, and Burden of Top 9 Cancers in a Developing Country. Razavi Int J Med. 2014; 2(3)
  • 12. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 2197-223[DOI]
  • 13. Department of Human Services . Victorian burden of disease study, Mortality and morbidity in 2001. 2005; : 228
  • 14. Mousavi Jarrahi Y, Mousavi Jarrahi A, Mohagheghi MA. The indirect cost of cancer in Tehran, preliminary report. Cancer Bullet. 2010; 2: 60-4
  • 15. Atlanta G. Cancer Facts & Figures 2010. 2010;
  • 16. Davari M, Yazdanpanah F, Aslani A, Hosseini M, Nazari AR, Mokarian F. The Direct Medical Costs of Breast Cancer in Iran: Analyzing the Patient's Level Data from a Cancer Specific Hospital in Isfahan. Int J Prev Med. 2013; 4(7): 748-54[PubMed]
  • 17. Wright MJ, Galea V, Barr RD. Proficiency of balance in children and youth who have had acute lymphoblastic leukemia. Phys Ther. 2005; 85(8): 782-90[PubMed]
  • 18. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992; 327(21): 1478-84[DOI][PubMed]
  • 19. Choi CW, Paek CW, Seo JH, Kim BS, Shin SW, Kim YH, et al. ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma. J Korean Med Sci. 2002; 17(5): 621-4[PubMed]
  • 20. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, et al. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994; 12(6): 1169-76[PubMed]
  • 21. Zinzani PL, Tani M, Molinari AL, Stefoni V, Zuffa E, Alinari L, et al. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Haematologica. 2002; 87(8): 816-21
  • 22. Zinzani PL, Barbieri E, Visani G, Gherlinzoni F, Perini F, Neri S, et al. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease. Haematologica. 1994; 79(6): 508-12[PubMed]
  • 23. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5): 365-76[PubMed]
  • 24. Taylor M. What is sensitivity analysis? 2009;
  • 25. Hutubessy R, Chisholm D, Edejer TT. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc. 2003; 1(1): 8[DOI][PubMed]
  • 26. Hackshaw A, Sweetenham J, Knight A. Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma? Br J Cancer. 2004; 90(7): 1302-5[DOI][PubMed]
  • 27. Woronoff-Lemsi MC, Arveux P, Limat S, Deconinck E, Morel P, Cahn JY. Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients. Bone Marrow Transplant. 1997; 20(11): 975-82[DOI][PubMed]
  • 28. Johnston KM, Marra CA, Connors JM, Najafzadeh M, Sehn L, Peacock SJ. Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada. Value Health. 2010; 13(6): 703-11[DOI][PubMed]
  • 29. Leese B, Collin R, Clark DJ. The costs of treating febrile neutropenia in patients with malignant blood disorders. Pharmacoeconomics. 1994; 6(3): 233-9[PubMed]
  • 30. Ray JA, Carr E, Lewis G, Marcus R. An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UK. Value Health. 2010; 13(4): 346-57[DOI][PubMed]
  • 31. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006; 106(10): 2258-66[DOI][PubMed]
  • 32. Hjermstad MJ, Oldervoll L, Fossa SD, Holte H, Jacobsen AB, Loge JH. Quality of life in long-term Hodgkin's disease survivors with chronic fatigue. Eur J Cancer. 2006; 42(3): 327-33[DOI][PubMed]
  • 33. Hasanpour Dehkordi A, Shaaban M. Relationship between cancer characteristics and quality of life in the cancer patients under chemotherapy referred to selected clinic of Tehran university of medical sciences. J Shahrekord Univ Med Sci. 2005; 6(4): 63-71
  • 34. Mols F, Aaronson NK, Vingerhoets AJ, Coebergh JW, Vreugdenhil G, Lybeert ML, et al. Quality of life among long-term non-Hodgkin lymphoma survivors: a population-based study. Cancer. 2007; 109(8): 1659-67[DOI][PubMed]
  • 35. Webster K, Cella D. Quality of life in patients with low-grade non-Hodgkin's lymphoma. Oncology (Williston Park, NY). 1998; 12(5): 697-714
  • 36. van Dis FW, Mols F, Vingerhoets AJ, Ferrell B, van de Poll-Franse LV. A validation study of the Dutch version of the Quality of Life-Cancer Survivor (QOL-CS) questionnaire in a group of prostate cancer survivors. Qual Life Res. 2006; 15(10): 1607-12[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments